Hedges and Woon et al 2003). Fourth, escitalopram has shown efﬁcacy in other anxiety disorders including social anxiety disorder, panic disorder, and generalized anxiety disorder (Dhillon et al 2006). More importantly, the one well-designed, double- blind, placebo-controlled trial to date of escitalopram in OCD (Stein et al 2007) found that escitalopram was superior to placebo for the treatment of OCD. Finally, the evidence to date suggests that escitalopram is reasonably well tolerated and has favorable pharmacokinetics, important features for a drug used to treat a highly chronic condition. Nonethe- less, given the few randomized, placebo-controlled trials of escitalopram for OCD to date, the role of escitalopram in the treatment of this condition will be better deﬁned by data from additional controlled trials. Clearly, more clinical data are needed before the role of escitalopram in OCD can be deﬁned. In addition to its clinical potential for the treatment of OCD, escitalopram may offer theoretical insight into the role of stereo-speciﬁc enantiomers in OCD. Together, these factors provide a rationale for additional trials of escitalopram in OCD. To further understand the role of escitalopram in the treatment of OCD, more data are required to evaluate its use with behavioral interventions such as exposure and response prevention treatment. Of equal importance is a better understanding of the role of escitalopram in the long- term treatment of OCD. References Abramowitz JS. 1997. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder:a quantitative review. J Consult Clin Psychol, 65:44–52. Ackerman DL, Greenland S. 2002. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychophar- macol, 22:309–17. Baldwin DS, Nair RV. 2005. Escitalopram in the treatment of generalized anxiety disorder. Expert Rev Neurother, 5:443–9. Bhatia MS, Sapra S. 2004. Escitalopram in trichotillomania. Eur Psychiatry, 19:239–40. Burke WJ. 2002. Escitalopram. Expert Opin Investig Drugs, 11:1477–86. Burke WJ, Gergel I, Bose A. 2002. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry, 63:331–6. Burke WJ, Kratochvil CJ. 2002. Stereoisomers in psychiatry: the case of escitalopram. Prim Care Companion J Clin Psychiatry, 4:20–4. Bystritsky A, Ackerman DL, Rosen RM, et al. 2004. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive dis- order using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry, 65:565–8. Carey PD, Warwick J, Niehaus DJ, et al. 2004. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry, 4:30. Chang JW, Kim CH, Lee JD, et al. 2003. Single photon emission com- puted tomography imaging in obsessive-compulsive disorder and for stereotactic bilateral anterior cingulotomy. Neurosurg Clin N Am, 14:237–50. Cosgrove GR, Rauch SL. 2003. Stereotactic cingulotomy. Neurosurg Clin N Am, 14:225–35. 460 Dannon PN, Sasson Y, Hirschmann S, et al. 2000. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol, 10:165–9. Davidson JR, Bose A, Korotzer A, et al. 2004. Escitalopram in the treat- ment of generalized anxiety disorder: double-blind, placebo controlled, ﬂexible-dose study. Depress Anxiety, 19:234–40. Davidson JR, Bose A, Nil R, et al. 2004. Long-term treatment of generalized anxiety disorder with escitalopram. Eur Psychiatry, 19(Suppl 1):S224. Dell’Osso B, Nestadt G, Allen A, et al. 2006. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry, 67:600–10. Dhillon S, Scott LJ, Plosker GL. 2006. Escitalopram:a review of its use in the management of anxiety disorders. CNS Drugs, 20:763–90. Eddy KT, Dutra L, Bradley R, et al. 2004. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev, 24:1011–30. Fallon BA, Mathew SJ. 2000. Biological therapies for obsessive-compulsive disorder. J Psychiatr Pract, 6:113–28. Fineberg NA, Tonnoir B, Lemming O, et al. 2007. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol, 17:430–9. Grant JE, Potenza MN. 2006. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol, 21:203–9. Hewlett WA, Vinogradov S, Agras WS. 1992. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol, 12:420–30. Hollander E, Friedberg JP, Wasserman S, et al. 2005. The case for the OCD spectrum. In Abramowitz JS, Houts AC (eds). Concepts and controversies in obsessive-compulsive disorder. New York: Springer. p 95–118. Hyttel J, Bogeso KP, Perregaard J, et al. 1992. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect, 88:157–60. Jang JH, Kwon JS, Jang DP, et al. 2006. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug- naive patients with obsessive-compulsive disorder. Am J Psychiatry, 163:1202–7. Jung HH, Kim CH, Chang JH, et al. 2006. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: long-term follow-up results. Stereotact Funct Neurosurg, 84:184–9. Kaplan A, Hollander E. 2003. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv, 54:1111–8. Karno M, Golding JM, Sorenson SB, et al. 1988. The epidemiology of obsessive-compulsive disorder in ﬁve US communities. Arch Gen Psychiatry, 45:1094–9. Kasper S, Stein DJ, Loft H, et al. 2005. Escitalopram in the treatment of social anxiety disorder:randomised, placebo-controlled, ﬂexible-dosage study. Br J Psychiatry, 186:222–6. Kirkcaldy RD, Kim TJ, Carney CP. 2004. A somatoform variant of obsessive-compulsive disorder: a case report of OCD presenting with persistent vomiting. Prim Care Companion J Clin Psychiatry, 6:195–8. Lader M, Stender K, Burger V, et al. 2004. Efﬁcacy and tolerability of escitalopram in 12- and 24 week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety, 19:241–8. Lepola UM, Loft H, Reines EH. 2003. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol, 18:211–7. McDougle CJ, Epperson CN, Pelton GH, et al. 2000. A double-blind, placebo-controlled study of risperidone addition in serotonin reup- take inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry, 57:794–801. McDougle CJ, Goodman WK, Leckman JF, et al. 1993. Limited therapeutic effect of addition of buspirone in ﬂuvoxamine-refractory obsessive- compulsive disorder. Am J Psychiatry, 150:647–9. Neuropsychiatric Disease and Treatment 2007:3(4)